CTLA4 and neoplasm: Immune checkpoint inhibitors are commonly used immunotherapy medications that boost the cytotoxicity and proliferation ability of tumor-infiltrating lymphocytes by blocking the binding of inhibitory receptors (including CTLA-4 and PD-1) (23).